Cellular Therapies in Endocrine Diseases

Abstract

Currently, no curative therapies are available for many malignant diseases and for autoimmune disorders. Over the past two decades, however, substantial progress has been made in our understanding of immunity and immune tolerance. Numerous of immune mechanisms were identified responsible for breaking the state of tolerance and for inducing specific cytotoxic immunity. In parallel, much knowledge has been gained on how immune tolerance can be re-induced in autoimmune diseases. Here, we would like to add value to the current advances in cellular therapy for treating endocrine cancer as well as for inducing immune tolerance in autoimmune diseases. In addition, new insights into stem cell research in autoimmune diseases are presented and future perspectives are given.

endocrine carcinoma - autoimmune diseases - dendritic cells - natural killer cells - regulatory T cells - clinical studies

References

• 1 Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells.  Nature. 1997;  385 257-260
• 2 Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology.  Hum Immunol. 2000;  61 65-73
• 3 Andersen MH, Keikavoussi P, Brocker EB, Schuler-Thurner B, Jonassen M, Sondergaard I, Straten PT, Becker JC, Kampgen E. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.  Int J Cancer. 2001;  94 820-824
• 4 Apostolou I, Boehmer H von. In vivo instruction of suppressor commitment in naive T cells.  J Exp Med. 2004;  199 1401-1408
• 5 Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats.  Surgery. 1972;  72 175-186
• 6 Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells.  Annu Rev Immunol. 2000;  18 767-811
• 7 Battaglia M, Roncarolo MG. In vivo neutralization of inflammatory cytokines might not be necessary for regulatory T-cell immunotherapy.  Nat Rev Immunol. 2007;  8 c2
• 8 Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories.  J Immunol Methods. 2002;  268 131-140
• 9 Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma.  J Clin Endocrinol Metab. 2004;  89 3413-3420
• 10 Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation.  Lancet. 1999;  353 370-373
• 11 Brossart P. Dendritic cells in vaccination therapies of malignant diseases.  Transfus Apher Sci. 2002;  27 183-186
• 12 Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+CD25+T-cells in type 1 diabetes.  Diabetes. 2005;  54 1407-1414
• 13 Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovic S. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.  Clin Cancer Res. 2000;  6 2175-2182
• 14 Butts CL, Shukair SA, Duncan KM, Harris CW, Belyavskaya E, Sternberg EM. Effects of dexamethasone on rat dendritic cell function.  Horm Metab Res. 2007;  39 404-412
• 15 Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A, Banchereau J. CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II.  Functional analysis. Blood. 1997;  90 1458-1470
• 16 Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo.  Proc Natl Acad Sci USA. 2001;  98 11521-11526
• 17 Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity.  Nat Rev Immunol. 2007;  7 622-632
• 18 Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.  Proc Natl Acad Sci USA. 1994;  91 123-127
• 19 Chen W, Jin W, Tian H, Sicurello P, Frank M, Orenstein JM, Wahl SM. Requirement for transforming growth factor beta1 in controlling T cell apoptosis.  J Exp Med. 2001;  194 439-453
• 20 Chen XL, Cao XD, Kang AJ, Wang KM, Su BS, Wang YL. In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma.  World J Gastroenterol. 2003;  9 1370-1373
• 21 Cissell MA, Zhao L, Sussel L, Henderson E, Stein R. Transcription factor occupancy of the insulin gene in vivo. Evidence for direct regulation by Nkx2.2.  J Biol Chem. 2003;  278 751-756
• 22 Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self.  Nat Immunol. 2001;  2 1032-1039
• 23 Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.  Blood. 2002;  100 174-177
• 24 Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.  Nature. 2001;  413 165-171
• 25 Dohrmann C, Gruss P, Lemaire L. Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas.  Mech Dev. 2000;  92 47-54
• 26 Doxsee CL, Riter TR, Reiter MJ, Gibson SJ, Vasilakos JP, Kedl RM. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells.  J Immunol. 2003;  171 1156-1163
• 27 Dudek RW, Lawrence Jr IE, Hill RS, Johnson RC. Induction of islet cytodifferentiation by fetal mesenchyme in adult pancreatic ductal epithelium.  Diabetes. 1991;  40 1041-1048
• 28 Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.  Nat Med. 1999;  5 405-411
• 29 Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.  Exp Hematol. 2006;  34 753-759
• 30 Fortis C, Ferrero E, Biffi M, Heltai S, Besana C, Bucci E, Tresoldi M, Rugarli C. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.  Cancer Immunol Immunother. 1991;  33 128-132
• 31 Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shiratori Y. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma.  J Gastroenterol Hepatol. 2004;  19 1121-1127
• 32 Gatzka M, Walsh CM. Apoptotic signal transduction and T cell tolerance.  Autoimmunity. 2007;  40 442-452
• 33 Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, is-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.  Clin Cancer Res. 2004;  10 2253-2264
• 34 Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.  Nature. 2002;  419 734-738
• 35 Haller MJ, Gottlieb PA, Schatz DA. Type 1 diabetes intervention trials 2007: where are we and where are we going?.  Curr Opin Endocrinol Diabetes Obes. 2007;  14 283-287
• 36 Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.  J Biol Response Mod. 1990;  9 546-555
• 37 Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Juttner E, Peters JH, Haring B, Leo R, Unger C, Azemar M. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study.  Prostate. 2007;  67 500-508
• 38 Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M. CD83+blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer.  Lancet. 1998;  352 1358
• 39 Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.  Cancer Metastasis Rev. 2005;  24 487-499
• 40 Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma.  Anticancer Res. 2004;  24 1861-1871
• 41 Jacobs B, Wuttke M, Papewalis C, Seissler J, Schott M. Dendritic cell subtypes and in vitro generation of dendritic cells.  Horm Metab Res. 2008;  40 99-107
• 42 Jaeckel E, Kretschmer K, Apostolou I, Boehmer H von. Instruction of Treg commitment in peripheral T cells is suited to reverse autoimmunity.  Semin Immunol. 2006;  18 89-92
• 43 Jaeckel E, Mpofu N, Saal N, Manns MP. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.  Horm Metab Res. 2008;  40 126-136
• 44 Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.  Immunity. 2003;  19 225-234
• 45 Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation.  Transpl Immunol. 2003;  11 267-276
• 46 Kadowaki N, Antonenko S, Ho S, Rissoan MC, Soumelis V, Porcelli SA, Lanier LL, Liu YJ. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells.  J Exp Med. 2001;  193 1221-1226
• 47 Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.  Proc Natl Acad Sci USA. 1998;  95 7556-7561
• 48 Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard PJ, Blazar BR. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.  Cancer Gene Ther. 1995;  2 39-46
• 49 Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.  Nat Immunol. 2002;  3 83-90
• 50 Klingemann H, Boissel L. Targeted cellular therapy with natural killer cells.  Horm Metab Res. 2008;  40 122-125
• 51 Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B, Permert J, Persson NH, Rafael E, Ryden M, Salmela K, Tibell A, Tufveson G, Nilsson B. Optimising islet engraftment is critical for successful clinical islet transplantation.  Diabetologia. 2008;  51 227-232
• 52 Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, Boehmer H von. Inducing and expanding regulatory T cell populations by foreign antigen.  Nat Immunol. 2005;  6 1219-1227
• 53 Kyewski B, Klein L. A central role for central tolerance.  Annu Rev Immunol. 2006;  24 571-606
• 54 Lee DD, Grossman E, Chong AS. Cellular therapies for type 1 diabetes.  Horm Metab Res. 2008;  40 147-154
• 55 Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.  Diabetes. 2005;  54 92-99
• 56 Lonyai A, Kodama S, Burger D, Davis M, Faustman DL. The promise of hox11+stem cells of the spleen for treating autoimmune diseases.  Horm Metab Res. 2008;  40 137-146
• 57 Makarenkova VP, Shurin GV, Tourkova IL, Balkir L, Pirtskhalaishvili G, Perez L, Gerein V, Siegfried JM, Shurin MR. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells.  J Neuroimmunol. 2003;  145 55-67
• 58 Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.  Adv Immunol. 2000;  74 181-273
• 59 Marzorati S, Pileggi A, Ricordi C. Allogeneic islet transplantation.  Expert Opin Biol Ther. 2007;  7 1627-1645
• 60 Melder RJ, Rosenfeld CS, Herberman RB, Whiteside TL. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man.  Cancer Immunol Immunother. 1989;  29 67-73
• 61 Miller GM, Andres ML, Gridley DS. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation.  Int J Oncol. 2003;  23 1585-1592
• 62 Miller JS, Soignier Y, Panoskaltsis-Mortari A, MacNearney SA, Yun GH, Fautsch SK, MacKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, MacGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.  Blood. 2005;  105 3051-3057
• 63 Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease.  Nat Rev Immunol. 2007;  7 665-677
• 64 Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression.  Trends Mol Med. 2007;  13 108-116
• 65 Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities.  J Immunol. 2003;  171 3385-3393
• 66 Monti P, Scirpoli M, Maffi P, Ghidoli N, De TF, Bertuzzi F, Piemonti L, Falcone M, Secchi A, Bonifacio E. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells 11.  J Clin Invest. 2008;  118 1806-1814
• 67 Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.  Clin Cancer Res. 1999;  5 1331-1338
• 68 Mullen Y, Maruyama M, Smith CV. Current progress and perspectives in immunoisolated islet transplantation.  J Hepatobiliary Pancreat Surg. 2000;  7 347-357
• 69 Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer.  Curr Cancer Drug Targets. 2007;  7 31-40
• 70 Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.  Cancer Immunol Immunother. 2008;  57 411-423
• 71 Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.  Ann Surg. 2002;  235 540-549
• 72 Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.  Nat Med. 1998;  4 328-332
• 73 Nishimura W, Kondo T, Salameh T, El KI, Dodge R, Bonner-Weir S, Sharma A. A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells.  Dev Biol. 2006;  293 526-539
• 74 Okubo Y, Shimada A, Kanazawa Y, Shigihara T, Oikawa Y, Imai T, Miyazaki J, Itoh H. Hyperplastic islets observed in “reversed” NOD mice treated without hematopoietic cells.  Diabetes Res Clin Pract. 2008;  79 18-23
• 75 Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S, Ikeguchi M. Decreased NKG2D expression on CD8+T cell is involved in immune evasion in patients with gastric cancer.  Clin Cancer Res. 2007;  13 382-387
• 76 Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, Willenberg HS, Schinner S, Cohnen M, Seissler J, Zacharowski K, Scherbaum WA, Schott M. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo.  J Immunol. 2008a;  180 1462-1470
• 77 Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T, Cupisti K, Raffel A, Chao L, Fenk R, Seissler J, Scherbaum WA, Schott M. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.  Horm Metab Res. 2008b;  40 108-116
• 78 Papewalis C, Wuttke M, Seissler J, Meyer Y, Kessler C, Jacobs B, Ullrich E, Willenberg H, Schinner S, Baehring T, Scherbaum WA, Schott M. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer.  Clin Cancer Res. 2008c;  , in press
• 79 Perone MJ, Bertera S, Tawadrous ZS, Shufesky WJ, Piganelli JD, Baum LG, Trucco M, Morelli AE. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice.  J Immunol. 2006;  177 5278-5289
• 80 Rabinovich GA, Ramhorst RE, Rubinstein N, Corigliano A, Daroqui MC, Kier-Joffe EB, Fainboim L. Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms.  Cell Death Differ. 2002;  9 661-670
• 81 Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells.  Nat Med. 2000;  6 278-282
• 82 Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood.  J Exp Med. 1994;  180 83-93
• 83 Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.  J Immunol Methods. 1996;  196 137-151
• 84 Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans.  Nat Rev Immunol. 2007;  7 585-598
• 85 Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.  N Engl J Med. 1987;  316 889-897
• 86 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines.  Nat Med. 2004;  10 909-915
• 87 Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich G. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.  Cancer Cell. 2004;  5 241-251
• 88 Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+CD25+CD4+natural regulatory T cells in dominant self-tolerance and autoimmune disease.  Immunol Rev. 2006;  212 8-27
• 89 Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.  Hum Immunol. 2006;  67 188-195
• 90 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.  J Exp Med. 1994;  179 1109-1118
• 91 Sander M, Sussel L, Conners J, Scheel D, Kalamaras J, Dela CF, Schwitzgebel V, Hayes-Jordan A, German M. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas.  Development. 2000;  127 5533-5540
• 92 Schendel DJ. Dendritic cell vaccine strategies for renal cell carcinoma.  Expert Opin Biol Ther. 2007;  7 221-232
• 93 Schott M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.  Endocr Relat Cancer. 2006;  13 779-795
• 94 Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum WA, Seissler J. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination.  Cancer Immunol Immunother. 2002;  51 663-668
• 95 Schott M, Feldkamp J, Schattenberg D, Seissler J, Scherbaum WA. Dendritic cell immuno-therapy in disseminated parathyroid carcinoma.  Lancet. 1999;  353 1188-1189
• 96 Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.  J Clin Endocrinol Metab. 2001;  86 4965-4969
• 97 Seissler J, Schott M. Generation of insulin-producing beta cells from stem cells – perspectives for cell therapy in type 1 diabetes.  Horm Metab Res. 2008;  40 155-161
• 98 Seliger B, Bock M, Ritz U, Huber C. High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors.  Int J Oncol. 2002;  20 349-353
• 99 Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.  Scand J Immunol. 1997;  46 625-632
• 100 Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood.  Science. 1999;  284 1835-1837
• 101 Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+progenitors into CD11c+CD80/86+DC capable of inducing a Th1-type response.  Eur J Immunol. 2007;  37 2834-2846
• 102 Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation.  J Exp Med. 2005;  202 583-588
• 103 Staeva-Vieira T, Peakman M, von HM. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.  Clin Exp Immunol. 2007;  148 17-31
• 104 Steinman RM. The dendritic cell system and its role in immunogenicity.  Annu Rev Immunol. 199;  19 271-296
• 105 Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, Diefenbach A, Yagita H, Godfrey DI, Smyth MJ. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.  J Exp Med. 2004;  199 879-884
• 106 Sussel L, Kalamaras J, Hartigan-O’Connor DJ, Meneses JJ, Pedersen RA, Rubenstein JL, German MS. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells.  Development. 1998;  125 2213-2221
• 107 Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den DP, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.  J Exp Med. 1999;  190 1669-1678
• 108 Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van BA, Liles TM, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.  Blood. 2002;  99 1517-1526
• 109 Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O, Gonzalez A, Berasain C, Berraondo P, Fortes P, Prieto J, Colombo MP, Chen L, Melero I. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma.  Cancer Res. 2006;  66 2442-2450
• 110 Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Eynde BJ Van den. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.  Nat Med. 2003;  9 1269-1274
• 111 Belle T Van, Herrath M von. Immunosuppression in islet transplantation.  J Clin Invest. 2008;  118 1625-1628
• 112 Verda L, Kim DA, Ikehara S, Statkute L, Bronesky D, Petrenko Y, Oyama Y, He X, Link C, Vahanian NN, Burt RK. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice.  Stem Cells. 2008;  26 381-386
• 113 Whiteside TL, Herberman RB. The biology of human natural killer cells.  Ann Ist Super Sanita. 1990;  26 335-348
• 114 Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1.  Cancer Immunol Immunother. 2006;  55 63-67
• 115 Wu L, Liu YJ. Development of dendritic-cell lineages.  Immunity. 2007;  26 741-750
• 116 Xu Q, Wang S, Xi L, Wu S, Chen G, Zhao Y, Wu Y, Ma D. Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway.  Gynecol Oncol. 2006;  101 132-139
• 117 Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-beta in the generation and expansion of CD4+CD25+regulatory T cells from human peripheral blood.  J Immunol. 2001;  166 7282-7289
• 118 You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.  Proc Natl Acad Sci USA. 2007;  104 6335-6340
• 119 Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity.  J Exp Med. 2002;  195 F9-14

Correspondence